FDA Recommends Against Blood Thinner Xarelto For Preventing Stroke All anti-coagulants can lead to bleeding or hemorrhaging, like Pradaxa, but other individuals have antidotes that can reverse the effects of the drug. Many research have identified that there are improved bleeding dangers in Xarelto customers, and several FDA Adverse Occasion Reports state that there have been situations of severe bleeding and even death. The FDA issued its most severe warning, called a black box warning,” warning that these who abruptly cease taking Xarelto and do not replace it with an additional blood thinning medication are at an enhanced threat of stroke. Individuals who believe they have been harmed by Xarelto side effects can elect to file a lawsuit against J&J. Xarelto use was expanded in November 2011 to lessen stroke and blood clot risks in patients with atrial fibrillation (irregular heart rhythms). A Florida lady filed a Xarelto side effects lawsuit in June that alleges her husband died after suffering a subdural hemorrhage. According to the Xarelto lawsuit, the womans husband was prescribed Xarelto in January 2012 to treat atrial fibrillation and suffered the subdural hemorrhage in June 2013. As Xarelto is made to avoid clotting, there is a danger that excessive bleeding might continue until Xarelto has exited the patients technique. For example, if there is bleeding close to a vital organ such as the brain, lungs, or kidneys, then the typical blood flow to that organ might be interrupted. Xarelto carries a boxed warning stating that early/premature discontinuation of Xarelto increases the danger of thrombotic events If use of Xarelto is discontinued for any explanation besides problematic bleeding or the completion of remedy, patients are advised to strongly contemplate making use of a diverse anticoagulant medication. Xarelto is prescribed to assist lessen the risk of threat of stroke and blood clots in folks with atrial fibrillation (not brought on by a heart valve difficulty) treat deep vein thrombosis and pulmonary embolism and to reduce the danger of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery. But the drug may also result in irreversible internal bleeding that can lead to hospitalization and death. At the time they introduced the medication, Johnson & Johnson and Bayer buried mention about the lack of an Xarelto reversal agent in the full prescribing data, indicating that they did not test for all attainable antidotes. Even following the hyperlink among Xarelto and severe bleeds became evident in post-marketing adverse event reports, the drug makers continued to promote the medication as secure and efficient, withholding information on the danger of irreversible bleeding. The lawyers at Saiontz & Kirk, P.A. are reviewing Xarelto situations for people all through the United States.